Sanofi to invest in a leading-edge production site in Singapore; continues to strengthen its vaccines manufacturing capacities
- Sanofi will invest €400 million over five years to create a unique vaccine production site in Singapore, pushing the boundaries of operations through cutting edge manufacturing and digital technologies.
- The new site will provide Sanofi with the ability to produce innovative vaccines on a massive scale for Asia, and quickly respond to future pandemic risks.
- The Singapore site will complement Sanofi’s existing manufacturing capacities in Europe and North America and will become a regional center of excellence for vaccines production in Asia.
PARIS – April 12, 2021 - Sanofi today announced a €400 million investment over five years to create a unique vaccine production center in Singapore, pushing the boundaries of operations through cutting edge manufacturing and digital technologies. In partnership with the Singapore Economic Development Board (EDB), the new site will mainly supply the Asian region and complement existing manufacturing capacities in Europe and North America.
The investment furthers Sanofi’s commitment to driving the future of vaccines by expanding manufacturing capabilities to ensure quality and scale, while responding to the risk of future pandemics. The project is expected to create up to 200 local jobs and enhance Singapore’s position as a regional innovation hub for the healthcare industry.
“As a major healthcare player, it’s our responsibility to act and to meet the unprecedented growing demands for vaccines. By investing in a new production site in Singapore, Sanofi is aiming to strengthen production capacity to meet ever-growing global demands on vaccines, and answer more rapidly to future pandemics,” said Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur. “We are very pleased by the strong collaboration with the Singapore Economic Development Board to achieve this exciting milestone.”
“Sanofi’s decision to locate its first-in-Asia digitally-enabled vaccine production center in Singapore, to supply markets in the region and beyond, is an endorsement of Singapore’s position as a leading centre for advanced manufacturing” said Dr Beh Swan Gin, Chairman, EDB. “EDB will continue to promote digitalization, automation and innovation to transform the manufacturing sector and create good jobs for Singaporeans.”
This factory will be designed around a central unit housing several fully digitalized modules that allow production of three to four vaccines simultaneously, versus only one in current industrial sites. In addition, the factory will have the flexibility to leverage multiple vaccine manufacturing technology platforms based on different cell types This modularity and flexibility will allow the production of a specific vaccine to be prioritized in a faster timeframe depending on public health needs.
The project is currently entering its design phase with construction expected to begin in Q3 2021. The five-year project will see the site fully operational in Q1 2026 once all qualifications and validations of the first manufactured vaccine have been completed.
In the context of Sanofi’s environmental strategy, the site is designed to be carbon-neutral, and to drastically reduce both resource consumption and waste production.
Editor’s Note: This investment in a new vaccine manufacturing facility further demonstrates Sanofi’s overall growth strategy, with vaccines contributing as a key growth driver through differentiated products, market expansion and new launches. It follows an announcement made in March to build a new facility in Canada to increase the Company’s global availability of high-dose influenza vaccine.
A world leader in vaccines
Sanofi, with its global vaccine entity Sanofi Pasteur, is a leading vaccine developer and manufacturer. Sanofi offers a portfolio of vaccines to protect children, adolescents, and adults from diseases such as influenza, infectious diseases, and endemic diseases.
With 16,000 employees and an international network of 12 industrial sites dedicated to vaccine manufacturing, Sanofi Pasteur’s vaccines protect more than half a billion people in the world.
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Sanofi, Empowering Life
Media Relations Contact
Tel.: +1 732-532-5318
Investor Relations Contacts Paris
Investor Relations Contacts North America
IR main line:
Tel.: +33 (0)1 53 77 45 45
|Sanofi Forward-Looking Statements|
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly, and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2020. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.